Japan Breast Cancer Research Group

Hiroji Iwata

Seigo Nakamura

Masakazu Toi

Hitoshi Tsuda

Futoshi Akiyama

Kenjiro Aogi

Nobuaki Sato

Katsumasa Kuroi

Masafumi Kurosumi

Shinji Ohno

Norikazu Masuda

An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.

Method for the administration of anti-cancer drugs

Growing community of inventors

Aichi, Japan

Hiroji Iwata